Reply

Hepatology

Volumn 65, Issue 6, 2017, Pages 2125-2126

  Su, Feng ^a   Ioannou, George N ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; LEDIPASVIR PLUS SOFOSBUVIR;

BLACK PERSON; CAUCASIAN; HUMAN; LETTER; LIVER CIRRHOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 85018709082     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29058     Document Type: Letter

References (1)

1. O'Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 2014;1:ofu110.